Publications 2016

1. Worah K, Mathan TS, Vu Manh TP, Keerthikumar S, Schreibelt G, Tel J, Duiveman-de Boer T, Skold AE, van Spriel AB, de Vries IJ, Huynen MA, Wessels HJ, Gloerich J, Dalod M, Lasonder E, Figdor CG, Buschow SI. Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function. Cell Rep, 2016. 16(11): 2953-66.

2. Gielen PR, Schulte BM, Kers-Rebel ED, Verrijp K, Bossman SA, Ter Laan M, Wesseling P, Adema GJ. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro Oncol, 2016. 18(9): 1253-64.

3. Potter VT, Iacobelli S, van Biezen A, Maertens J, Bourhis JH, Passweg JR, Yakhoub-Agha I, Tabrizi R, Bay JO, Chevallier P, Chalandon Y, Huynh A, Cahn JY, Ljungman P, Craddock C, Lenhoff S, Russell NH, Fegueux N, Socie G, Benedetto B, Meijer E, Mufti GJ, de Witte T, Robin M, Kroger N. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. Biol Blood Marrow Transplant, 2016. 22(9): 1615-20.

4. Schulte BM, Gielen PR, Kers-Rebel ED, Prosser AC, Lind K, Flodstrom-Tullberg M, Tack CJ, Elving LD, Adema GJ. Enterovirus Exposure Uniquely Discriminates Type 1 Diabetes Patients with a Homozygous from a Heterozygous Melanoma Differentiation-Associated Protein 5/Interferon Induced with Helicase C Domain 1 A946T Genotype. Viral Immunol, 2016. 29(7): 389-97.

5. Meddens MB, Pandzic E, Slotman JA, Guillet D, Joosten B, Mennens S, Paardekooper LM, Houtsmuller AB, van den Dries K, Wiseman PW, Cambi A. Actomyosin-dependent dynamic spatial patterns of cytoskeletal components drive mesoscale podosome organization. Nat Commun, 2016. 7: 13127.

6. Westdorp H, Fennemann FL, Weren RD, Bisseling TM, Ligtenberg MJ, Figdor CG, Schreibelt G, Hoogerbrugge N, Wimmers F, de Vries IJ. Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother, 2016. 65(10): 1249-59.

7. Bol KF, van den Bosch T, Schreibelt G, Mensink HW, Keunen JE, Kilic E, Japing WJ, Geul KW, Westdorp H, Boudewijns S, Croockewit SA, van Rossum MM, de Goede AL, Naus NC, van der Graaf WT, Gerritsen WR, de Klein A, Punt CJ, Figdor CG, Cohen VM, Paridaens D, de Vries IJ. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology, 2016. 123(10): 2265-7.

8. Bull C, Collado-Camps E, Kers-Rebel ED, Heise T, Sondergaard JN, den Brok MH, Schulte BM, Boltje TJ, Adema GJ. Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation. Immunol Cell Biol, 2016.

9. den Brok MH, Bull C, Wassink M, de Graaf AM, Wagenaars JA, Minderman M, Thakur M, Amigorena S, Rijke EO, Schrier CC, Adema GJ. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat Commun, 2016. 7: 13324.

10. Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EHJG, Duiveman-de Boer T, van de Rakt MWMM, Scharenborg NM, De Boer AJ, Pots JM, Nordkamp MAMO, van Oorschot TGM, Tel J, Winkels G, Petry K, Blokx WAM, van Rossum MM, Welzen MEB, Mus RDM, Croockewit SAJ, Koornstra RHT, Jacobs JFM, Kelderman S, Blank CU, Gerritsen WR, Punt CJA, Figdor CG, de Vries IJM. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016. 22(9): 2155-66.

11. Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, Annino L, Venditti A, Voso MT, Mazzone C, Magro D, De Fabritiis P, Muus P, Alimena G, Mancini M, Hagemeijer A, Paoloni F, Vignetti M, Fazi P, Meert L, Ramadan SM, Willemze R, de Witte T, Baron F. Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol, 2016. 34(9): 972-9.

12. Bol KF, Aarntzen EHJG, Pots JM, Nordkamp MAMO, van de Rakt MWMM, Scharenborg NM, de Boer AJ, van Oorschot TGM, Croockewit SAJ, Blokx WAM, Oyen WJG, Boerman OC, Mus RDM, van Rossum MM, van der Graaf CAA, Punt CJA, Adema GJ, Figdor CG, de Vries IJM, Schreibelt G. Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. Cancer Immunology Immunotherapy, 2016. 65(3): 327-39.

13. Porter JB, de Witte T, Cappellini MD, Gattermann N. New insights into transfusion-related iron toxicity: Implications for the oncologist. Critical Reviews in Oncology Hematology, 2016. 99: 261-71.

14. Stavenga M, Leavis HL, de Witte TM, Raymakers RAP. Allogeneic stem cell transplantation in a patient with myelodysplastic syndrome and polyarteritis nodosa: a case report and systematic review. Annals of Hematology, 2016. 95(4): 645-7.

15. Stavenga M, Leavis HL, de Witte TM, Raymakers RA. Allogeneic stem cell transplantation in a patient with myelodysplastic syndrome and polyarteritis nodosa: a case report and systematic review. Ann Hematol, 2016. 95(4): 645-7.

16. De Vries J, Figdor C. Immunotherapy: Cancer vaccine triggers antiviral-type defences. Nature, 2016. 534(7607): 329-31.

17. Vasaturo A, Halilovic A, Bol KF, Verweij DI, Blokx WA, Punt CJ, Groenen PJ, van Krieken JH, Textor J, de Vries IJ, Figdor CG. T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Res, 2016. 76(12): 3496-506.

18. Schulte BM, Kers-Rebel ED, Bottino R, Piganelli JD, Galama JM, Engelse MA, de Koning EJ, Adema GJ. Distinct activation of primary human BDCA1(+) dendritic cells upon interaction with stressed or infected beta cells. Clin Exp Immunol, 2016. 184(3): 293-307.

19. de Witte T, Amadori S. The optimal dosing of gemtuzumab ozagamicin: where to go from here?. Haematologica, 2016. 101(6): 653-4.

20. Bull C, Heise T, Adema GJ, Boltje TJ. Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis. Trends in Biochemical Sciences, 2016. 41(6): 519-31.

21. Hoogenboom M, Eikelenboom D, den Brok MH, Veltien A, Wassink M, Wesseling P, Dumont E, Futterer JJ, Adema GJ, Heerschap A. In vivo MR guided boiling histotripsy in a mouse tumor model evaluated by MRI and histopathology. NMR Biomed, 2016. 29(6): 721-31.

22. Kroesen M, Bull C, Gielen PR, Brok IC, Armandari I, Wassink M, Looman MW, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ. Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma. Oncoimmunology, 2016. 5(6): e1164919.

23. Boudewijns S, Westdorp H, Koornstra RH, Aarntzen EH, Schreibelt G, Creemers JH, Punt CJ, Figdor CG, de Vries IJ, Gerritsen WR, Bol KF. Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. J Immunother, 2016. 39(6): 241-8.

24. Boudewijns S, Bol KF, Schreibelt G, Westdorp H, Textor JC, van Rossum MM, Scharenborg NM, de Boer AJ, van de Rakt MW, Pots JM, van Oorschot TG, Duiveman-de Boer T, Olde Nordkamp MA, van Meeteren WS, van der Graaf WT, Bonenkamp JJ, de Wilt JH, Aarntzen EH, Punt CJ, Gerritsen WR, Figdor CG, de Vries IJ. Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients. Oncoimmunology, 2016. 5(7): e1191732.

25. Roncador G, Engel P, Maestre L, Anderson AP, Cordell JL, Cragg MS, Serbec VC, Jones M, Lisnic VJ, Kremer L, Li D, Koch-Nolte F, Pascual N, Rodriguez-Barbosa JI, Torensma R, Turley H, Pulford K, Banham AH. The European antibody network's practical guide to finding and validating suitable antibodies for research. MAbs, 2016. 8(1): 27-36.

26. van Rijn A, Paulis L, te Riet J, Vasaturo A, Reinieren-Beeren I, van der Schaaf A, Kuipers AJ, Schulte LP, Jongbloets BC, Pasterkamp RJ, Figdor CG, van Spriel AB, Buschow SI. Semaphorin 7A Promotes Chemokine-Driven Dendritic Cell Migration. Journal of Immunology, 2016. 196(1): 459-68.

27. Lubbert M, Suciu S, Hagemeijer A, Ruter B, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Muus P, Pfluger KH, Schaefer HE, Bogatyreva L, Aul C, de Witte T, Ganser A, Becker H, Huls G, van der Helm L, Vellenga E, Baron F, Marie JP, Wijermans PW, Grp EL, Grp GMS. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Annals of Hematology, 2016. 95(2): 191-9.

28. Dingjan I, Verboogen DR, Paardekooper LM, Revelo NH, Sittig SP, Visser LJ, Mollard GF, Henriet SS, Figdor CG, Ter Beest M, van den Bogaart G. Lipid peroxidation causes endosomal antigen release for cross-presentation. Sci Rep, 2016. 6: 22064.

29. Eich C, Lasonder E, Cruz LJ, Reinieren-Beeren I, Cambi A, Figdor CG, Buschow SI. Proteome Based Construction of the Lymphocyte Function-Associated Antigen 1 (LFA-1) Interactome in Human Dendritic Cells. PLoS One, 2016. 11(2): e0149637.

30. Eich C, Manzo C, de Keijzer S, Bakker GJ, Reinieren-Beeren I, Garcia-Parajo MF, Cambi A. Changes in membrane sphingolipid composition modulate dynamics and adhesion of integrin nanoclusters. Scientific Reports, 2016. 6: 20693.

31. Jones EL, Wee JL, Demaria MC, Blakeley J, Ho PK, Vega-Ramos J, Villadangos JA, van Spriel AB, Hickey MJ, Hammerling GJ, Wright MD. Dendritic Cell Migration and Antigen Presentation Are Coordinated by the Opposing Functions of the Tetraspanins CD82 and CD37. Journal of Immunology, 2016. 196(3): 978-87.

32. de Winde CM, Veenbergen S, Young KH, Xu-Monette ZY, Wang XX, Xia Y, Jabbar KJ, van den Brand M, van der Schaaf A, Elfrink S, van Houdt IS, Gijbels MJ, van de Loo FAJ, Bennink MB, Hebeda KM, Groenen PJTA, van Krieken JH, Figdor CG, van Spriel AB. Tetraspanin CD37 protects against the development of B cell lymphoma. Journal of Clinical Investigation, 2016. 126(2): 653-66.

33. Xu-Monette ZY, Li L, Byrd JC, Jabbar KJ, Manyam GC, Maria de Winde C, van den Brand M, Tzankov A, Visco C, Wang J, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi WW, Huh J, Ponzoni M, Ferreri AJ, Moller MB, Parsons BM, Winter JN, Wang M, Hagemeister FB, Piris MA, Han van Krieken J, Medeiros LJ, Li Y, van Spriel AB, Young KH. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. Blood, 2016. 128(26): 3083-100.

34. Cremers EM, van Biezen A, de Wreede LC, Scholten M, Vitek A, Finke J, Platzbecker U, Beelen D, Schwerdtfeger R, Volin L, Harhalakis N, Blijlevens N, Nagler A, Kroger N, de Witte T. Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT. Ann Hematol, 2016. 95(12): 1971-8.

35. Bakdash G, Buschow SI, Gorris MA, Halilovic A, Hato SV, Skold AE, Schreibelt G, Sittig SP, Torensma R, Duiveman-de Boer T, Schroder C, Smits EL, Figdor CG, de Vries IJ. Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Res, 2016. 76(15): 4332-46.

36. Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer T, Worah K, de Haas N, Buschow SI, de Vries IJ, Figdor CG, Hato SV. Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology, 2016. 5(8): e1192739.

37. Boudewijns S, Koornstra RH, Westdorp H, Schreibelt G, van den Eertwegh AJ, Geukes Foppen MH, Haanen JB, de Vries IJ, Figdor CG, Bol KF, Gerritsen WR. Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. Oncoimmunology, 2016. 5(8): e1201625.

38. Bol KF, Schreibelt G, Gerritsen WR, de Vries IJ, Figdor CG. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Clin Cancer Res, 2016. 22(8): 1897-906.

39. Tel J, Koornstra R, de Haas N, van Deutekom V, Westdorp H, Boudewijns S, van Erp N, Di Blasio S, Gerritsen W, Figdor CG, de Vries IJM, Hato SV. Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. Journal of Translational Medicine, 2016. 14: 88.

40. Gram AM, Oosenbrug T, Lindenbergh MF, Bull C, Comvalius A, Dickson KJ, Wiegant J, Vrolijk H, Lebbink RJ, Wolterbeek R, Adema GJ, Griffioen M, Heemskerk MH, Tscharke DC, Hutt-Fletcher LM, Wiertz EJ, Hoeben RC, Ressing ME. The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells. PLoS Pathog, 2016. 12(4): e1005550.

41. Bol KF, Aarntzen EH, Hout FE, Schreibelt G, Creemers JH, Lesterhuis WJ, Gerritsen WR, Grunhagen DJ, Verhoef C, Punt CJ, Bonenkamp JJ, de Wilt JH, Figdor CG, de Vries IJ. Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. Oncoimmunology, 2016. 5(1): e1057673.

42. Dolen Y, Kreutz M, Gileadi U, Tel J, Vasaturo A, van Dinther EA, van Hout-Kuijer MA, Cerundolo V, Figdor CG. Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. Oncoimmunology, 2016. 5(1): e1068493.

43. Sittig SP, Bakdash G, Weiden J, Skold AE, Tel J, Figdor CG, de Vries IJM, Schreibelt G. A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. Mediators of Inflammation, 2016. 2016: 3605643.

44. Wimmers F, Aarntzen EHJG, Duiveman-deBoer T, Figdor CG, Jacobs JFM, Tel J, de Vries IJM. Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. Oncoimmunology, 2016. 5(1): e1067745.

45. Varghese J, Holz C, Neuhaus P, Bernardi M, Boehm A, Ganser A, Gore S, Heaney M, Hochhaus A, Hofmann WK, Krug U, Muller-Tidow C, Smith A, Weltermann A, de Witte T, Hehlmann R, Dugas M. Key Data Elements in Myeloid Leukemia. Stud Health Technol Inform, 2016. 228: 282-6.

46. Torensma R. Immune Containment of Cancer Stem Cells. Immunochemistry & Immunopathology, 2016. 2: 2.

47. Langemeijer SM, Mariani N, Knops R, Gilissen C, Woestenenk R, de Witte T, Huls G, van der Reijden BA, Jansen JH. Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients. PLoS One, 2016. 11(11): e0165582.